Resources Repository
-
ArticlePublication 2016Extended CEA: Home-Based Neonatal Care in Rural India
This chapter examines the health, economic benefits, and government costs associated with scaling up a …
This chapter examines the health, economic benefits, and government costs associated with scaling up a publicly financed home-based neonatal care package in rural India. This extended cost-effectiveness analysis considers two intervention scenarios against a baseline of no home-based neonatal care, both of which would utilize community health workers - one would provide coverage to approximately 7 out of 10 rural newborns, and the other would provide coverage to 9 out of 10 rural newborns.
Economics/Finance | Child/Nutrition | Priority Setting/Ethics | Cost-Effectiveness Analysis | Social Determinants | Health Systems | Health/Medicine | Asia & Pacific -
ArticlePublication 2015Extended CEA: Surgical Access in Ethiopia
This chapter presents an extended cost-effectiveness analysis of strategies to improve access to surgical care …
This chapter presents an extended cost-effectiveness analysis of strategies to improve access to surgical care in rural Ethiopia, providing information on the health and financial risk protection benefits of policies. This chapter is from Essential Surgery, the first volume in the Disease Control Priorities, third edition (DCP3) series. The volume presents data on the surgical burden of disease, disability, congenital anomalies, and trauma, along with health impact and economic analyses of procedures, platforms, and packages…
Economics/Finance | Child/Nutrition | Priority Setting/Ethics | Costing Methods | Cost-Effectiveness Analysis | Maternal/Reproductive Health | Health Systems | Health/Medicine | Sub-Saharan Africa -
ReviewPublication 2013Role of Health Economic Analyses in Vaccine Decision Making
Beginning in the 20th century with the consideration of the seven-valent pneumococcal conjugate vaccine in …
Beginning in the 20th century with the consideration of the seven-valent pneumococcal conjugate vaccine in the US, cost effectiveness became a topic of discussion when a vaccine was being considered for universal use by the US Advisory Committee on Immunization practices (ACIP). In 2008, the ACIP began using formal criteria for the presentation of such data and their inclusion in ACIP discussions. More recently, the U.S. Institute of Medicine has recommended that health economic considerations play a…
Economics/Finance | Infectious Diseases | Priority Setting/Ethics | Cost-Effectiveness Analysis | Health Systems | Health/Medicine | North America -
ArticlePublication 2013Estimated Mortality Impact of Vaccinations 2011–2020 in 73 GAVI Alliance Countries
From August to December 2011, a multidisciplinary group with expertise in mathematical modeling was constituted …
From August to December 2011, a multidisciplinary group with expertise in mathematical modeling was constituted by the GAVI Alliance and the Bill & Melinda Gates Foundation to estimate the impact of vaccination in 73 countries supported by the GAVI Alliance. The number of deaths averted in persons projected to be vaccinated during 2011–2020 was estimated for ten antigens: hepatitis B, yellow fever, Haemophilus influenzae type B (Hib), Streptococcus pneumoniae, rotavirus, Neisseria meningitidis serogroup A, Japanese…
Health Outcomes | Economics/Finance | Infectious Diseases | Mathematical Models | State-Transition | Dynamic Transmission | Microsimulation | Global Governance | Health/Medicine | Science/Technology | Sub-Saharan Africa | Middle East & North Africa | Latin America & Caribbean | Asia & Pacific -
GuidelinesPublication 2013Economic Analyses to Support Decisions about HPV Vaccination in Low- and Middle-Income Countries: Consensus Report and Guide
Low- and middle-income countries need to consider economic issues such as cost-effectiveness, affordability and sustainability …
Low- and middle-income countries need to consider economic issues such as cost-effectiveness, affordability and sustainability before introducing a program for human papillomavirus (HPV) vaccination. However, many such countries lack the technical capacity and data to conduct their own analyses. This report describes the consensus of an expert group convened by the World Health Organization, prioritizing key issues to be addressed when considering economic analyses to support HPV vaccine introduction in these countries. The expert group…
Health Outcomes | Economics/Finance | Infectious Diseases | Costing Methods | Cost-Effectiveness Analysis | Chronic Disease/Risk | Health Systems | Health/Medicine | Science/Technology | Sub-Saharan Africa | Middle East & North Africa | Latin America & Caribbean | Asia & Pacific